TRAns-Femoral Access Intravascular Lithotripsy Comparison With PTA in TAVI

Обзор

To compare the effectiveness and the safety of femoral-iliac IVL versus balloon only PTA for successful deployment of transfemoral transcatheter aortic valve prosthesis.

Подробное описание

Trans-femoral (TF) access has been identified as the best vascular approach for trans-catheter aortic valve implantation (TAVI) in the most recent European Guidelines for the treatment of valvular heart disease. Nevertheless, the TF approach is not possible in a substantial number of TAVI candidates, mainly due to the presence of important peripheral arterial disease (PAD) that is perceived as a contraindication. The presence of PAD limiting TF-TAVI feasibility has always remained a challenging scenario. The concept of preparing TF access through balloon dilatation in case of PAD had been developed and, in this context, percutaneous transluminal angioplasty (PTA) with plain-balloon has been investigated, although available literature is scarce. Intra-vascular lithotripsy (IVL) was proved effective and safe to treat calcified peripheral arteries and such new technology bares the potential for being applied in TF TAVI in patients with concomitant PAD. The rationale is that the Shockwave IVL balloon inflated at low pressure modifies the vessel rigidity with creation of multiple longitudinal and transversal cracks in the calcium present within the vessel wall. Thus, the improved vessel compliance facilitates the successful passage of the valve delivery system resulting in higher rates of procedural success and lower risk for crossover to surgery, vessel injury and major complications.

Вмешательства

• Устройство Trans-femoral TAVI
  Trans-femoral TAVI (Trans-catheter Aortic Valve Implantation) with calcified ilio-femoral arteries via PTA (Percutaneous transluminal angioplasty ) or IVL (Intra-vascular Lithotripsy)

Первичные конечные точки

• Feasibility and safety on the trans-femoral (TF) approach [Срок оценки: Index procedure - 1 Month]

Вторичные конечные точки (9)

• MAEs [Срок оценки: Within 30 days after index procedure]
• Vascular and bleeding complications [Срок оценки: Within 30 days after index procedure]
• Device-related vascular complication [Срок оценки: Discharge, 1-months, 6-months]
• Residual stenosis, Degree of dissection, Final Flow [Срок оценки: Index procedure]
• Procedural time duration, amount of contrast media and radiation dose. [Срок оценки: Index procedure]
• Centralized analysis of the angiographic parameters [Срок оценки: Index procedure]
• Stent Implantation [Срок оценки: Index procedure]
• Functional capacity of the inferior limbs [Срок оценки: 6-months]
• Patency at the distal level of the vascular access site [Срок оценки: 6-months]

Критерии участия

Критерии включения

• Age > 18 years
• Written informed consent
• Diagnosis of symptomatic severe aortic stenosis
• Patient undergoing TAVI according to local institutional protocol and following Heart Team discussion.
• High-quality Contrast-enhanced ECG gated computed tomography (CT) scan of the heart, aorta and low-limb arteries
• Calcific severe PAD raising concerns within the Heart Team and judged as "arguable" for TF approach following angiography or CT-scan evaluation (hostile femoral access), with a RefD>/=5 mm and a MLD>/=3 mm.
• Hostility score >/= 23 in at least one segment of the axis under evaluation.

Критерии исключения

• Life expectancy < 1 year
• Subject has active infection requiring antibiotic therapy.
• STS score ≥8%
• Leriche syndrome or other forms of total occlusion of the aorta or both iliac axes.
• Planned target limb major amputation (above the ankle).
• History of prior endovascular or surgical procedure on the index limb within the past 30 days or planned within 30 days of the index procedure.
• Subject in whom antiplatelet or anticoagulant therapy is contraindicated.
• Subject has known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pre-treated.
• Subject has known allergy to urethane, nylon, or silicone.
• Subject is participating in another research study involving an investigational agent (pharmaceutical, biologic, or medical device) that has not reached the primary endpoint.
• Subject has other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment.
• The use of specialty balloons, re-entry or atherectomy devices

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения

Когортное

Центры проведения

Италия · 5 центров

• AOU Cardiology Ancona — Ancona
• AULLS3 Cardiology Mestre — Mestre
• AULSS2 Cardiology Treviso — Treviso
• AOUI Cardiology Verona — Verona
• AULLS8 Cardiology Vicenza — Vicenza

Идентификаторы

NCT: NCT05873842 · RO-230301

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗